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To evaluate the effectiveness of ginsenoside Rg3 alone or in combination with cyclophosphamide (CPA) 
on tumor growth and angiogenesis in human lung cancer, 54 female athymic mice were transplanted 
with lung cancer cells (A549) which then were randomly divided into 4 groups: Ginsenoside Rg3 group, 
CPA group, ginsenoside Rg3 plus CPA group and control group. Ginsenoside Rg3 of 3.0 mg/kg 
(once/day for 10 days) and CPA of 20.0 mg/kg (once/day for 10 days) were intraperitoneally given to 
mice for consecutive 10 days. Seven mice selected from each group were sacrificed 18 days later. The 
survival time of the remaining 7 mice in each group was recorded. The life elongation rate, proliferating 
cell nuclear antigen labeling index (PCNALI), expression of vascular endothelial cell growth factor 
(VEGF) and microvessel density (MVD) in the tumor tissues were evaluated. The quality of life of mice 
with administration of ginsenoside Rg3 alone or ginsenoside Rg3 plus CPA were better with longer 
survival time, when compared with other groups. The PCNALI, MVD and VEGF expression in mice of the 
treated groups were significantly lowered when compared with that of the control group. Additionally, 
the MVD of mice in groups with treatment of ginsenoside Rg3 alone or ginsenoside Rg3 plus CPA were 
lower than that in the CPA group. Tumor growth and angiogenesis in lung cancer were profoundly 
inhibited by ginsenoside Rg3 alone or in combination with CPA. The synergistic anticancer effects of 
ginsenoside Rg3 and CPA improved the survival time in lung cancer. 
 





With the development of Chinese herbal medicine, more 
and more researchers are interested in the exploitation of 
novel anticancer components in herbs. Ginsenoside Rg3, 
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anticancer activity. Studies have indicated its suppressive 
effects on the angiogenesis in Lewis cancer (Lee et al., 
2009), breast cancer (Zhang et al., 2008) and on invasion 
and metastasis of intestinal adenocarcinomas and B16 
melenoma (Liu et al., 2004; Mochizuki et al., 1995; Iishi et 
al., 2004) as well as proliferation of prostate cancer cells 
(Kim et al., 2004; Keum et al., 2003). Recently, evidence 
has disclosed the therapeutic effects of continuous low 
dose chemotherapy combined with other inhibitors of 
angiogenesis (Hanahan et al., 2000; Klement et al., 
2000). The results demonstrated that this method was 
more effective in the suppression of tumor growth than 





on lung cancer remain to be evaluated.  
In this study, we aimed to evaluate the effectiveness of 
ginsenoside Rg3 alone or in combination with 
cyclophosphamide (CPA) on the tumor growth and 
angiogenesis in human lung cancer. 
 
 
MATERIALS AND METHODS 
 
Ginsenoside Rg3, provided by the Department of Basic Medicine of 
Shandong University, was extracted from American ginseng with 
≥99.5% of purity quotient. Six-week old female athymic mice were 
purchased from the department of Experimental Animal Center of 
Shandong University. The mouse monoclonal antibodies specific to 
CD31, vascular endothelial cell growth factor (VEGF) and 
proliferating cell nuclear antigen (PCNA) were purchased from 
Santa Cruz Co. (Santa Cruze, USA).  
Human lung cancer cell line A549 was obtained from the 
Department of Basic Medicine of Shandong University and cultured 
in RPMI1640 supplemented with 10% fetal bovine serum. 28 
female athymic mice were subcutaneously transplanted with 0.2 ml 
(1 × 10
7
/ml) A549 cell suspension in the armpit of right anterior limb. 
These mice were randomly divided into 4 groups (n = 14 for each): 
Ginsenoside Rg3 group, CPA group, ginsenoside Rg3 plus CPA 
group and control group. Ginsenoside Rg3 was intraperitoneally 
administrated at a dose of 3.0 mg/kg (once/day for 10 days) and 
CPA of 20.0 mg/kg (once/day for 10 days). The mice in the control 
group received saline. Seven mice selected from each group were 
sacrificed 18 days later. The survival time of the remaining 7 mice in 
each group was recorded. During the experiment, the survival time 
was recorded within forty days after tumor transplantation. 
Additionally, the life elongation rate was analyzed. Tumor tissues 
were fixed immediately in 10% paraformaldehyde and embedded in 
paraffin. Proliferative activity of lung cancer cells was evaluated by 
immunohistochemical staining with mouse monoclonal PCNA 
antibody (1:100) and the number of positive cells was counted at 
×400 magnifications. Subsequently, proliferating cell nuclear 
antigen labeling index (PCNALI) was calculated. 
Vascularization was expressed by MVD (micro-vascular density). 
The micro-vascular was evaluated by immunostaining of 
endothelium with mouse monoclonal CD31-PECAM antibody 
(1:100). The number of CD31 immunostained blood vessels was 
quantified at ×200 magnification. The values from five different 
fields were averaged and presented as mean ± standard deviation.  
VEGF positive cells were stained with yellow brown in the 
cytoplasm. The intensity of the immunoreactive reaction were 
graded as 0, no immunoreactivity; 1, weak intensity; 2, moderate 
intensity; 3, strong intensity. Positive percentage were graded as 0, 
<10%; 1, 10 to 24%; 2, 25 to 49%; 3, 50 to 75%; 4, ≥75. After 
adding the scores of intensity and positive percentage, we rescaled 
to score 0 to 1 as negative (-), 2 to 3 as weak expression (1+), 4 to 
5 as moderate expression (2+) and above 5 as strong expression 
(3+), and the immunoreactivity was scored semi quantitatively as 
the intensity of the immunoreactive reaction and positive percent of 





The results were expressed with mean ± standard deviation. 
Statistical analysis was performed by LSD test and one way 
analysis of variance for multiple comparisons in evaluation of tumor 
weight and number of living day. Nemenyi test for two comparisons 
and Kruskal Wallis test for multiple comparisons were performed in 
the analysis of PCNALI, MVD (micro-vascular density) and VEGF. A 
value   of   P<0.05   was   considered   as   statistically   significant.  






Effects of ginsenoside Rg3 and CPA on life 
elongation 
 
40 days after tumor transplantation, the number of mice 
that survived in ginsenoside Rg3, CPA, ginsenoside Rg3 
plus CPA and control groups was 3, 2, 3 and 0, 
respectively. The survival time of mice with lung cancer in 
the ginsenoside Rg3, CPA and ginsenoside Rg3 plus 
CPA groups was longer than in the control group and the 
life elongation rate reached 98.2% in the mice of 
ginsenoside Rg3 plus CPA group (Table 1). The results 
demonstrate that ginsenoside Rg3 prolonged survival 
time of mice with lung cancer. Furthermore, the ginseno-
side Rg3 and CPA conferred the synergistic therapeutic 
effects on the lung cancer. 
 
 
Effects of ginsenoside Rg3 and CPA on tumor cell 
proliferation and angiogenesis 
 
Table 2 and Figure 1 show that the number of PCNA 
positive cells and PCNALI in the treated groups was 
lower than that in the control group. These findings show 
that the ginsenoside Rg3, CPA or ginsenoside Rg3 in 
combination with CPA could inhibit the proliferation of 
A549 cells which leads to the suppression of tumor 
growth.  
The density of blood vessels in tumor tissues was 
assessed by CD31-PECAM immunostaining. The MVD in 
the ginsenoside Rg3, CPA and ginsenoside Rg3 plus 
CPA groups was significantly lowered when compared 
with control group. Furthermore, in the ginsenoside Rg3 
and ginsenoside Rg3 plus CPA groups, it was lower than 
CPA group (Table 2 and Figure 2). VEGF positive cells 
found in the ginsenoside Rg3, CPA and ginsenoside Rg3 
plus CPA groups were markedly decreased when com-
pared with control group, and there was no significant 
difference among the treated groups (Table 3 and Figure 
3). The results show that ginsenoside Rg3 inhibited tumor 
angiogenesis and the angiosuppressive effects of 





Chemotherapy is the treatment of choice for a variety of 
malignant tumors, which together with surgery and radio-
therapy constitute the traditional therapeutic methods for 
cancer. Although, chemotherapy is effective in combating 
against the tumor growth and metastasis, the mortality of 
cancer remains high. For example, 5-year survival rate of 
lung cancer remains low after conventional treatment 
(Davis et al., 2004). Thus, numerous studies have been 
conducted to explore novel therapies   for   cancers   
(Nguyen et al., 1998).   Anti-angiogenesis is  a  promising  




Table 1. Effect of ginsenoside Rg3 and CPA on life elongation of mice. 
 
Group Number of mice Living day Life elongation rate (%) 
Control 7 13.59±6.21 - 
Rg3 7 23.81±9.22** 74.5 
CPA 7 25.89±10.08** 90.2 
CPA+Rg3 7 27.22±8.11** 98.2 
 




Table 2. Inhibitory effects of ginsenoside Rg3 and CPA on tumor cell proliferation and angiogenesis 
(PCNALI and MVD in different groups). 
 
Group PCNALI (%) Number of vessel (MVD) 
Control 69.1±10.7 28.3±3.1 
Rg3 53.5±14.9* 23.0±2.64** 
CPA 43.1±12.3** 18.9±2.14** 
CPA+Rg3 35.5±12.7** 10.8±2.88** 
 







Figure 1. Immunohistochemical staining of PCNA. PCNA positive cells have yellow brown granules in nucleus. A: Control group; B: 






Figure 2. Immunohistochemical staining of CD31. The blood vessels in tumor tissues are stained with yellow brown. A: Control group; B: 




approach for the treatment of lung cancer. The rationale, 
as set forth by Folkman and others (Fukushima, 1983), 
states that establishing a state of counterbalancing 
between apoptosis and tumor cell proliferation by 
inhibiting angiogenesis induced by tumor and thus 
depriving tumors of essential nutrients and oxygen, 
leading to a quiescent state in which tumor expansion is 
stalled (Ellis et al., 2001). Ginsenoside Rg3, the major 
active component of ginseng, exerts angiosuppressive 
effects in numerous cancers (Yue et al., 2006; Chen et 
al., 2005). In this study, the results show that ginsenoside 
Rg3 inhibited the tumor growth and angiogenesis in lung 
cancer. Studies have confirmed that VEGF played an 
important role in the angiogenesis, and its expression 
was correlated with MVD (Maria et al., 2005). Our study 
discloses      that       ginsenoside       Rg3      significantly  




Table 3. Inhibitory effect of ginsenoside Rg3 and CPA on expression of VEGF.  
 
Group Number of mice 
VEGF Expression 
P value 
- + ++ +++ 
Control 7 0 0 1 6  
Rg3 7 2 4 1 0 ＜0.05* 
CPA 7 2 4 0 1 ＜0.05* 
CPA+Rg3 7 1 5 1 0 ＜0.05* 
 






Figure 3. Immunohistochemical staining of VEGF. VEGF positive cells have yellow brown granules
 
in the cytoplasm. A: 




decreased the expression of VEGF in lung cancer. These 
findings indicate that ginsenoside Rg3 could inhibit the 
tumor growth through its angiosuppressive effects. To 
prove the anti-cancer effects of ginsenoside Rg3, we 
assess the proliferative activity of lung cancer cells 
through PCNALI. PCNA is the polymerase δ accessory 
protein and synthesized in the early G1 and S phases of 
cell cycle when DNA synthesis is dominant. Therefore, 
PCNA can reflect the DNA replication. Furthermore, the 
metabolism and DNA replication in tumor cells represent 
the proliferative activity. Thus, PCNA is frequently used 
as an indicator of proliferative activity of tumor cells 
(Isozaki et al., 1996; Niu et al., 2002). Ginsenoside Rg3 
inhibits the PCNA expression that causes the reduced 
proliferative activity of lung cancer. Based on these 
results, we postulate that ginsenoside Rg3 may be an 
effective inhibitor of angiogenesis. However, in contrast 
to the data generated from animal studies, the previous 
results of various clinical trials aiming at evaluating angio-
genic inhibitors in cancer therapy have been equivocal. A 
strategy combining continuous low dose chemotherapy 
and anti-angiogenic therapy has been developed recently 
and used in the experimental treatment of malignant 
tumors such as breast cancer, retinoblastoma, lymphoma 
and leukemia (Overmoyer et al., 2007; Bello et al., 2001; 
Morioka et al., 2003). The combination of low dose 
chemotherapy and anti-angiogenesis conferred more 
effective anti-cancer effects than conventional chemo-
therapy. This study evaluates the effectiveness of the 
combination of anti-angiogenic therapy and chemo-
therapy in the treatment of lung cancer. The results  show 
that the combination of ginsenoside Rg3 and CPA 
prolonged the survival time of mice with lung cancer 
when compared with the treatment with CPA or 
ginsenoside Rg3 alone. Therefore, the combination of 
ginsenoside Rg3 and CPA has advantages in anti-cancer 
over ginsenoside Rg3 or CPA alone. Additionally, 
ginsenoside Rg3 and CPA exerted synergistic 
angiosuppressive effects confirm by the decreased MVD 
and VEGF expression. All these findings aforementioned 
demonstrate that the combination of ginsenoside Rg3 
and CPA was more effective in suppressing cancer 





Taken together, this study suggests that ginsenoside 
Rg3, alone or in combination with CPA inhibits cancer 
growth and angiogenesis in lung cancer. Furthermore, 
the combination of ginsenoside Rg3 and CPA confers 
synergistic angiosuppressive effects and improves the 
quality of life of mice with lung cancer. The combination 
of chemotherapy and antiangiogenic therapy may be a 
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